The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial
Sponsor: University of Central Florida
Terminated
Time and resource constraints
Other terminated trials from University of Central Florida
A PHASE4 clinical study on Raynaud Phenomenon, this trial is terminated or withdrawn. The trial is conducted by University of Central Florida and has accumulated 10 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE4
-
Sep 2021 — Dec 2022 [monthly]
Terminated PHASE4
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Terminated PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Nov 2018 — Apr 2020 [monthly]
Recruiting PHASE4
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE4
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE4
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Central Florida
For direct contact, visit the study record on ClinicalTrials.gov .